This is the logo of the provider
ADA 2025 20 - 23 June 2025

Oral Semaglutide and Cardiovascular Outcomes by Baseline A1c and BMI in People with Type 2 Diabetes in the SOUL Trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Diabetes
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)